 Vol.37, No.1, Oct. 2009 |
| 10th annual meeting of the Japan Society of Clinical Pharmacological Studies / The 27th Aso-Kujyu Conference on Clinical Pharmacology
|
| Vol.37, Suppl XXVII 2009 |
| Learning from Experience and New Challenges for the Future
|
| Vol.36, Suppl XXVI 2009 |
| Clinical science : Principles and practice - Science, law and humanity - |
| Vol.36, No.3, Apr. 2009 |
| Microdosing clinical trials of biologics |
| Vol.36, No.2, Dec. 2008 |
| Drug development and Medical Research Act in the Netherlands |
| Vol.36, No.1, Aug. 2008 |
The symposium on Deep Brain Stimulation (DBS) therapy for Psychiatric Disorders
At the 47th meeting of the Japan Society for Stereotactic and Functional Neurosurgery |
| Vol.35, No.3, Jun. 2008 |
| J-CLIPNET - Bases for early phase global clinical development |
| Vol.35, No.2, Dec. 2007 |
| The international meeting for promotion of global clinical development in Beppu |
| Vol.35, No.1, Sep. 2007 |
| A handbook for IRB members |
| Vol.35, Suppl XXV 2007 |
| Japan's Critical Path Opportunities |
| Vol.34, No.3, May 2007 |
| Safety information: reporting, dissemination, and analysis |
| Vol.34, No.2, Apr. 2007 |
| What is the future of obstetric medicine? |
| Vol.34, No.1, Feb. 2007 |
| CIOMS Guidelines for Biomedical Research |
| Vol.34, Suppl XXIV 2006 |
| What is the TGN 1412 case ? |
| Vol.33, No.3, Oct. 2006 |
| Basis of translational research: Academia-oriented clinical trials and new drug and medical technology development |
| Vol.33, Suppl XXIII 2006 |
| Development, Evaluation and Approval of New Drugs |
| Vol.33, No.2, Apr. 2006 |
| Position and role of the Asian and Oceanic regions in drug development |
| Vol.33, No.1, Dec. 2005 |
| ARO and IRB: Business-academia collaboration |
| Vol.32, No.2・3, Sep. 2005 |
| Risk management of pharmaceuticals ―product management and project management― |
| Vol.32, Suppl XXII 2005 |
| Global Development Strategies of New Drugs |
| Vol.32, No.1, Apr. 2005 |
| Clinical trial registration and the issue of "Mixed health insurance" |
| Vol.32, Suppl XXI 2004 |
Scientific and ethical evaluation of regenerative medicine
Focus on bone marrow and fetal stem cell clinical research |
| Vol.31, No.3, Sep. 2004 |
| Actual status of the new drug approval review system |
| Vol.31, Suppl XX 2004 |
| Forefront of New Drug Development Strategies |
| Vol.31, No.2, Apr. 2004 |
| The regulatory situations of clinical trials in the US, Europe and Asia |
| Vol.31, No.1, Dec. 2003 |
| The changing situation of clinical trials and support systems: Actual problems and how to solve them |
| Vol.30, No.2･3, Sep. 2003 |
| Clinical research in the "Bio-Genome Century" and the revised Pharmaceutical Affairs Law |
| Vol.30, Suppl XIX 2003 |
| Simultaneous, Worldwide Development Strategies |
| Vol.30 Suppl XVIII, 2003 |
| 有害事象の診断学 |
| Vol.30, No.1, Oct. 2002 |
Quality assurance of investigator-oriented clinical research in Japan
-Current status and efforts towards future development- |
| Vol.29, No.2･3, May 2002 |
| Knowledge management and knowledge sharing |
| Vol. 29 Suppl XVII, 2002 |
| Bridging Strategies and Pharmacogenomics |
| Vol. 29 No. 1, Nov. 2001 |
| Drug safety-current status and future perspectives |
| Vol. 29 Suppl XVI, 2001 |
| Clinical Evaluation of OTC Drugs and Traditional Drugs |
| Vol. 28 Suppl XV, 2001 |
| Bridging Strategies |
| Vol. 28 No. 3, Jun 2001 |
| The 2000 revision to the Declaration of Helsinki and ethics in this era of globalization |
| Vol. 28 No. 2, Jan. 2001 |
| Support systems for clinical trials under the new GCP |
| Vol. 28 No. 1, Oct. 2000 |
| External quality assurance in clinical trials |
| Vol. 27 Suppl XIV, 2000 |
| World wide view on development and evaluation of switched and direct OTC |
| Vol. 27 No. 3, Apr. 2000 |
| Information disclosure on clinical trials and international public health |
| Vol. 27 No. 2, Dec. 1999 |
| Present Status of Clinical Trials and Supporting Systems in Three Regions (Japan, the US and Europe) |
| Vol. 27 No. 1, Sep. 1999 |
| Application of Statistical Principles for Clinical Trials |